Aerpace Industries Ltd
534733Aerpace Industries Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (14 weeks in). Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aerpace Industries Ltd trades at ₹38.5, in a confirmed uptrend and 14 weeks into that stage. That is +28.3% against its own 200-day average. It sits at 82% of a 52-week range of ₹32 to ₹40. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹38.5 it trades +28.3% versus its 200-day average and sits at 82% of its 52-week range (₹32–₹40).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +21% while the NIFTY 500 moved −6% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
P/E does not price Aerpace Industries Ltd — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read.
Aerpace Industries Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
4-Factor Sector Score
40.5/100 — rank 57 of 58 in Trading · 32% evidence confidence · provisional, ranked below fully-evidenced peers
Aerpace Industries Ltd scores 40.5 out of 100 against the 58 companies it is compared with in Trading, ranking 57. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 13 + 5.5 + 10 + 12 = 40.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aerpace Industries Ltd reported ₹0.0 Cr of revenue in the Jun 26 quarter. The last full year, FY26, came in at ₹0.0 Cr. The last four reported quarters add to ₹0.0 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.
FY26 revenue came in at ₹0.0 Cr (null on the year). The latest quarter (Jun 26) printed ₹0.0 Cr, null year on year.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for Aerpace Industries Ltd — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for Aerpace Industries Ltd.
🚨 Why the margin moved: operating margin went −88.0 pp year on year while gross margin went +89.4 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aerpace Industries Ltd posted a net loss of ₹4.2 Cr in the Jun 26 quarter. The full FY26 year was a loss of ₹16.0 Cr. The same quarter a year earlier lost ₹1.8 Cr. 11 of the last 11 reported quarters were loss-making.
Jun 26 profit was ₹−4.2 Cr, null year on year. On the full year, FY26 printed ₹−16.0 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Aerpace Industries Ltd's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was ₹−3.0 Cr of operating cash against ₹−16.0 Cr of profit. After ₹20.0 Cr of capital spending, ₹−23.0 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of ₹−3.0 Cr against reported profit of ₹−16.0 Cr, leaving free cash of ₹−23.0 Cr after ₹20.0 Cr of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aerpace Industries Ltd does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran ₹76.0 Cr over the last 3 years. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of ₹76.0 Cr over the last 3 fiscal years against ₹3.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹57.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Aerpace Industries Ltd earns a ROCE of −22% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here.
FY26 ROCE is −22%.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Aerpace Industries Ltd carries ₹40.0 Cr of borrowings against ₹37.0 Cr of equity in FY26, a debt-to-equity of 1.08. Operating profit covers the interest bill −14×. Over 3 years borrowings went from ₹2.0 Cr to ₹40.0 Cr. Capital spending ran ₹76.0 Cr across the last 3 of those years.
FY26: borrowings of ₹40.0 Cr against equity of ₹37.0 Cr — a debt-to-equity of 1.08. Operating profit covers the interest bill −14×. Over 3 years borrowings went from ₹2.0 Cr to ₹40.0 Cr while capital spending ran ₹76.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 5.5 points of Aerpace Industries Ltd over 8 quarters, the biggest move on the register. That takes promoters to 45.3% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −5.5 points over 8 quarters to 45.3%.
🚨 Why the register moved: promoters drove it (−5.5 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aerpace Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Magnus Steel & Infra Ltd517320 | 67.1/100Thin evidence · provisional56% evidence | 27.5/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 11.9/20 RS sector — · RS bench 46.1% · 1Y 1004.7%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.5 + 18.5 + 9.2 + 11.9 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Vision Infra Equipment Solutions LtdVIESL | 66.8/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.9/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 13.8× · PEG — 15% evidence | 17.1/20 RS sector 12.8% · RS bench 34.7% · 1Y 65.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.9 + 10.9 + 17.1 = 66.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Nupur Recyclers LtdNRL | 66.6/100Favorable setup87% evidence | LEADER | 22.1/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 8.0/20 P/E 63× · PEG — 50% evidence | 19.9/20 RS sector 84.5% · RS bench 117.1% · 1Y 116.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 16.6 + 8 + 19.9 = 66.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Rashi Peripherals LtdRPTECH | 65.5/100Favorable setup75% evidence | LEADER | 24.3/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.6/20 P/E 19.8× · PEG — 15% evidence | 15.9/20 RS sector 64.7% · RS bench 92.3% · 1Y 202.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.6 + 15.9 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 62.7/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.2/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 25.1 + 17.4 + 10.2 + 10 = 62.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Mangalam Global Enterprise LtdMGEL | 61.7/100Mixed-positive evidence80% evidence | BASING | 25.1/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.9/25 ROCE 17% · OPM 1.9% 95% evidence | 11.0/20 P/E 13.7× · PEG — 15% evidence | 9.7/20 RS sector -4.3% · RS bench 15.3% · 1Y -11%5 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 15.9 + 11 + 9.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Pramara Promotions LtdPRAMARA | 61.6/100Mixed-positive evidence69% evidence | 22.3/35 Revenue 72.7% · PAT 100% · OPM change 1 pp 59% evidence | 14.3/25 ROCE 15% · OPM 14.6% 95% evidence | 14.3/20 P/E 14.2× · PEG — 50% evidence | 10.7/20 RS sector 7.9% · RS bench -60.1% · 1Y -63.3%10 of 12 weeks ahead 70% evidence | |
| Exact sum: 22.3 + 14.3 + 14.3 + 10.7 = 61.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tembo Global Industries LtdTEMBO | 60.7/100Mixed-positive evidence80% evidence | TURNING | 21.7/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.4× · PEG — 15% evidence | 9.2/20 RS sector -16.2% · RS bench 1.9% · 1Y 1.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.5 + 11.3 + 9.2 = 60.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Arisinfra Solutions LtdARIS | 58.4/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.0/25 ROCE 15.6% · OPM 11% 95% evidence | 10.6/20 P/E 17.2× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 15.2% · 1Y -12.1%7 of 12 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15 + 10.6 + 11.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Ivalue Infosolutions LtdIVALUE | 58.4/100Mixed-positive evidence65% evidence | ASLEEP | 20.2/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.2× · PEG — 15% evidence | 8.4/20 RS sector — · RS bench -10.3% · 1Y -20.9%5 of 12 weeks ahead 25% evidence |
| Exact sum: 20.2 + 18.6 + 11.2 + 8.4 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Euro Pratik Sales LtdEUROPRATIK | 57.7/100Mixed-positive evidence78% evidence | ASLEEP | 14.9/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.4/25 ROCE 36.9% · OPM 26% 100% evidence | 15.4/20 P/E 22.6× · PEG 0.62 65% evidence | 8.0/20 RS sector — · RS bench -26.3% · 1Y -18.9%5 of 12 weeks ahead 25% evidence |
| Exact sum: 14.9 + 19.4 + 15.4 + 8 = 57.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Singer India LtdSINGERIND | 57.3/100Thin evidence · provisional52% evidence | 26.1/35 Revenue 43.5% · PAT 100% · OPM change 6.5 pp 71% evidence | 10.2/25 ROCE 10.9% · OPM 2.5% 76% evidence | 10.1/20 P/E 25.9× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 9.7% · 1Y — 25% evidence | |
| Exact sum: 26.1 + 10.2 + 10.1 + 10.9 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.2/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.1/25 ROCE 18.9% · OPM 6% 76% evidence | 8.8/20 P/E 247× · PEG — 15% evidence | 13.3/20 RS sector -2.3% · RS bench 17.8% · 1Y 28.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.1 + 8.8 + 13.3 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Sudarshan Pharma Industries Ltd543828 | 55.2/100Mixed-positive evidence82% evidence | FADING | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.4/20 P/E 37× · PEG — 50% evidence | 12.6/20 RS sector 8.1% · RS bench 28.7% · 1Y 40.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 13.7 + 8.4 + 12.6 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 55.0/100Mixed-positive evidence75% evidence | TURNING | 17.9/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.2/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 104× · PEG — 15% evidence | 16.8/20 RS sector 4.9% · RS bench 25.8% · 1Y 23.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 11.2 + 9.1 + 16.8 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Onix Solar Energy LtdONIXSOLAR | 54.7/100Mixed-positive evidence69% evidence | ASLEEP | 20.6/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 11.7/25 ROCE 11.3% · OPM 30% 76% evidence | 10.0/20 P/E 27.7× · PEG — 15% evidence | 12.4/20 RS sector 68.4% · RS bench -22.9% · 1Y 24.9%0 of 1 week ahead 70% evidence |
| Exact sum: 20.6 + 11.7 + 10 + 12.4 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Patel Retail LtdPATELRMART | 53.8/100Mixed-positive evidence65% evidence | ASLEEP | 17.9/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.4/25 ROCE 15.6% · OPM 6.1% 95% evidence | 10.7/20 P/E 16.9× · PEG — 15% evidence | 10.8/20 RS sector — · RS bench 8% · 1Y -5.2%4 of 12 weeks ahead 25% evidence |
| Exact sum: 17.9 + 14.4 + 10.7 + 10.8 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Bizotic Commercial Ltd543926 | 52.9/100Thin evidence · provisional58% evidence | TURNING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.7/25 ROCE 26.8% · OPM 8% 76% evidence | 9.0/20 P/E 40.2× · PEG — 50% evidence | 5.5/20 RS sector -84% · RS bench -0.7% · 1Y -77.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.7 + 9 + 5.5 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Prostarm Info Systems LtdPROSTARM | 51.7/100Mixed-positive evidence65% evidence | TURNING | 16.6/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.0/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 22.3× · PEG — 15% evidence | 8.7/20 RS sector — · RS bench -4.7% · 1Y -31.7%2 of 12 weeks ahead 25% evidence |
| Exact sum: 16.6 + 16 + 10.4 + 8.7 = 51.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Pervasive Commodities Ltd517172 | 51.0/100Thin evidence · provisional52% evidence | TURNING | 16.6/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.4/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.6 + 14.4 + 10 + 10 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.7/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.7 + 12 + 11.1 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Fabtech Technologies LtdFABTECH | 49.4/100Thin evidence · provisional57% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 8.4/20 RS sector — · RS bench -12.2% · 1Y -27.1%0 of 12 weeks ahead 25% evidence |
| Exact sum: 17.5 + 12.4 + 11.1 + 8.4 = 49.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Yogi LtdYOGI | 48.6/100Thin evidence · provisional58% evidence | TURNING | 20.1/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 12.6% · OPM 2.6% 76% evidence | 9.4/20 P/E 54.9× · PEG — 15% evidence | 9.1/20 RS sector -6.5% · RS bench 2.2% · 1Y -6.7%0 of 1 week ahead 70% evidence |
| Exact sum: 20.1 + 10 + 9.4 + 9.1 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24SG Mart LtdSGMART | 48.2/100Mixed-negative evidence93% evidence | LEADER | 13.6/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 75.3× · PEG 1.92 65% evidence | 18.0/20 RS sector 27.3% · RS bench 50.1% · 1Y 104.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 8.4 + 8.2 + 18 = 48.2 · Decision use: Price leads the evidence: RS versus the benchmark is 50.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25Shiv Aum Steels LtdSHIVAUM | 46.9/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 6.6/20 P/E 79.6× · PEG — 50% evidence | 12.1/20 RS sector — · RS bench 65.9% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 6.6 + 12.1 = 46.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Dhunseri Ventures LtdDVL | 46.7/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 39% 95% evidence | 12.4/20 P/E 5.1× · PEG — 50% evidence | 12.4/20 RS sector -8.2% · RS bench 11.7% · 1Y -23.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.4 + 12.4 + 12.4 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.8/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.6/25 ROCE 7.6% · OPM — 80% evidence | 10.8/20 P/E 15.3× · PEG — 15% evidence | 5.5/20 RS sector -28.7% · RS bench -6.2% · 1Y -21.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 22.8 + 7.6 + 10.8 + 5.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Hexa Tradex LtdHEXATRADEX | 42.4/100Mixed-negative evidence65% evidence | TURNING | 17.0/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.2/20 RS sector -17.1% · RS bench 0.7% · 1Y -10%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 10 + 9.2 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29MMTC LtdMMTC | 42.0/100Mixed-negative evidence96% evidence | ASLEEP | 15.0/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.8/20 P/E 41.9× · PEG 0.92 100% evidence | 3.4/20 RS sector -22.4% · RS bench -6% · 1Y -14.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 7.8 + 15.8 + 3.4 = 42 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Cropster Agro Ltd523105 | 41.1/100Mixed-negative evidence69% evidence | BASING | 15.3/35 Revenue 28.4% · PAT 6.5% · OPM change 1.7 pp 95% evidence | 11.7/25 ROCE 12.4% · OPM 9.8% 76% evidence | 10.8/20 P/E 14.2× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -74.2% · 1Y -87.9%0 of 5 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 3.3 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31RRP Semiconductor LtdRRP | 40.8/100Thin evidence · provisional54% evidence | 11.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.6/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.0/20 RS sector 65.3% · RS bench 0.8% · 1Y 23.7%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.2 + 5.6 + 10 + 14 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Le Merite Exports LtdLEMERITE | 40.0/100Thin evidence · provisional57% evidence | 18.0/35 Revenue — · PAT — · OPM change -15.5 pp 45% evidence | 6.8/25 ROCE 9.9% · OPM -10.7% 95% evidence | 9.1/20 P/E 94.5× · PEG — 15% evidence | 6.1/20 RS sector -9% · RS bench -68.5% · 1Y -95%0 of 2 weeks ahead 70% evidence | |
| Exact sum: 18 + 6.8 + 9.1 + 6.1 = 40 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Hardwyn India LtdHARDWYN | 39.9/100Mixed-negative evidence87% evidence | ASLEEP | 13.5/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.3/25 ROCE 4.8% · OPM 13% 95% evidence | 12.5/20 P/E 50.8× · PEG — 50% evidence | 1.6/20 RS sector -38.6% · RS bench -25.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.3 + 12.5 + 1.6 = 39.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Blue Pearl Agriventures LtdBPAGRI | 39.2/100Mixed-negative evidence69% evidence | 20.0/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.2/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -90.8%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20 + 6.2 + 8.7 + 4.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Adani Enterprises LtdADANIENT | 39.0/100Mixed-negative evidence93% evidence | ASLEEP | 14.1/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.3/25 ROCE 5.8% · OPM 15% 100% evidence | 7.6/20 P/E 161× · PEG 1.96 65% evidence | 9.0/20 RS sector -1.4% · RS bench 17.9% · 1Y 14.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.3 + 7.6 + 9 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Neueon Corporation LtdNEUEON | 37.8/100Thin evidence · provisional59% evidence | TURNING | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.9/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 12.7% · RS bench 25.1% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.9 + 10 + 14.8 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 37PTC India LtdPTC | 37.7/100Mixed-negative evidence82% evidence | ASLEEP | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.2/20 P/E 9× · PEG — 50% evidence | 4.6/20 RS sector -20.7% · RS bench -4.1% · 1Y -7.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.7 + 9.2 + 4.6 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Riddhi Siddhi Gluco Biols Ltd524480 | 36.9/100Mixed-negative evidence82% evidence | TURNING | 12.3/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.4/20 P/E 35.8× · PEG — 50% evidence | 11.7/20 RS sector 4% · RS bench 23.7% · 1Y 26.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 6.5 + 6.4 + 11.7 = 36.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Kothari Industrial Corporation LtdKOTIC | 34.7/100Adverse evidence63% evidence | TURNING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 2.0/25 ROCE -11.4% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.0/20 RS sector -58.6% · RS bench -29.1% · 1Y -71.9%0 of 12 weeks ahead 70% evidence |
| Exact sum: 18.7 + 2 + 10 + 4 = 34.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40BN Agrochem LtdBNAGROCHEM | 32.3/100Adverse evidence77% evidence | BASING | 12.8/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.2/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 130× · PEG — 15% evidence | 6.3/20 RS sector -16.7% · RS bench -17.4% · 1Y -38.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 4.2 + 9 + 6.3 = 32.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Shanti Overseas (India) LtdSHANTI | 31.5/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 12.1/20 P/E 3× · PEG — 50% evidence | 3.6/20 RS sector -60.4% · RS bench -49.7% · 1Y -46.8%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.5 + 12.1 + 3.6 = 31.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Uniphos Enterprises LtdUNIENTER | 31.3/100Adverse evidence69% evidence | ASLEEP | 12.3/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.5/25 ROCE 0.8% · OPM — 80% evidence | 9.9/20 P/E 29.9× · PEG — 50% evidence | 4.6/20 RS sector -43.6% · RS bench -19.9% · 1Y -41.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4.5 + 9.9 + 4.6 = 31.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | 2.9/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -30.3% · 1Y -52.7%0 of 11 weeks ahead 70% evidence | |
| Exact sum: 2.9 + 7.7 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Susan Electricals India Ltd544793 | 58.9/100Thin evidence · provisional31% evidence | TURNING | 20.6/35 Revenue — · PAT — · OPM change 7.8 pp 26% evidence | 18.1/25 ROCE 37% · OPM 11.9% 76% evidence | 10.2/20 P/E 25.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 1 week ahead 0% evidence |
| Exact sum: 20.6 + 18.1 + 10.2 + 10 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Q-Line Biotech LtdQLINE | 58.0/100Thin evidence · provisional31% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 10 pp 13% evidence | 19.8/25 ROCE 22.4% · OPM 31% 95% evidence | 10.1/20 P/E 27.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 18.1 + 19.8 + 10.1 + 10 = 58 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46DC Infotech & Communication LtdDCI | 57.4/100Thin evidence · provisional35% evidence | 18.4/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.7/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.3/20 P/E 22.7× · PEG — 15% evidence | 11.0/20 RS sector — · RS bench 10.5% · 1Y —1 of 1 week ahead 25% evidence | |
| Exact sum: 18.4 + 17.7 + 10.3 + 11 = 57.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.0/100Thin evidence · provisional32% evidence | 20.9/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.3/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 74.6% · 1Y 44.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.9 + 15.3 + 8.6 + 12.2 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48SK Minerals & Additives Ltd544584 | 55.5/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.1/25 ROCE 26.2% · OPM 10.7% 76% evidence | 9.9/20 P/E 28.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 7 weeks ahead 0% evidence |
| Exact sum: 16.5 + 19.1 + 9.9 + 10 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Proventus Agrocom LtdPROV | 55.3/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.7/25 ROCE 11.5% · OPM 1.8% 95% evidence | 11.3/20 P/E 48.3× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 44.2% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.5 + 12.7 + 11.3 + 11.8 = 55.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Arvaya Healthcare LtdARVAYA | 54.7/100Thin evidence · provisional19% evidence | 18.6/35 Revenue — · PAT — · OPM change 46.1 pp 10% evidence | 12.3/25 ROCE — · OPM 13% 30% evidence | 11.4/20 P/E 3.9× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 104.2% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 12.3 + 11.4 + 12.4 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -12%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52Shah Foods Ltd519031 | 53.5/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 233× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 69.1% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Manbro Industries Ltd512595 | 51.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.2/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 83.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.2 + 10 + 9.5 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54Satani Bearings Ltd505703 | 45.4/100Thin evidence · provisional38% evidence | BREAKING OUT | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5323× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 27.6% · 1Y 169.8%4 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.6 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Keto Motors Ltd537392 | 43.2/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 6745× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 191.6% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 16.2 + 6 + 8.5 + 12.5 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56A-1 LtdA1L | 40.9/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.7/20 P/E 383× · PEG — 15% evidence | 5.4/20 RS sector -24.5% · RS bench -16% · 1Y -11.7%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.7 + 8.7 + 5.4 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Aerpace Industries Ltdthis page534733 | 40.5/100Thin evidence · provisional32% evidence | TURNING | 13.0/35 Revenue — · PAT -80% · OPM change — 33% evidence | 5.5/25 ROCE -21.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.0/20 RS sector — · RS bench 50.7% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 13 + 5.5 + 10 + 12 = 40.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Prabhatam Infra Venture LtdPRABHATAM | 39.2/100Thin evidence · provisional22% evidence | 16.1/35 Revenue — · PAT -80% · OPM change — 8% evidence | 3.1/25 ROCE -97.1% · OPM -23.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.1 + 3.1 + 10 + 10 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aerpace Industries Ltd's share price today?
Aerpace Industries Ltd trades at ₹38.5. The company is valued at ₹592 Cr. The stock sits at 82% of its 52-week range of ₹32–₹40, +28.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 1 October 2026.
What were Aerpace Industries Ltd's latest quarterly results?
Aerpace Industries Ltd reported revenue of ₹0.0 Cr and a net loss of ₹4.2 Cr for the Jun 26 quarter. Earnings per share were ₹−0.27. — as of 1 October 2026.
What is Aerpace Industries Ltd's revenue?
Aerpace Industries Ltd reported revenue of ₹0.0 Cr in the Jun 26 quarter. For the full FY26 fiscal year, revenue was ₹0.0 Cr. — as of 1 October 2026.
What is Aerpace Industries Ltd's profit?
Aerpace Industries Ltd earned ₹−4.2 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹−16.0 Cr. — as of 1 October 2026.
What is Aerpace Industries Ltd's market cap?
Aerpace Industries Ltd's market capitalisation is ₹592 Cr at a share price of ₹38.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 1 October 2026.
Does Aerpace Industries Ltd pay a dividend?
No — Aerpace Industries Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 1 October 2026.
How is Aerpace Industries Ltd performing?
Aerpace Industries Ltd is in a confirmed uptrend, 14 weeks in. This describes what the data did, not a rating. — as of 1 October 2026.
Is Aerpace Industries Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading +28.3% versus its 200-day average and at 82% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 1 October 2026.
Will Aerpace Industries Ltd's share price go up?
This page publishes no price forecast for Aerpace Industries Ltd. What it measures instead: the share price is ₹38.5, the price is in a confirmed uptrend 14 weeks in. Direction is not something this site claims to know. — as of 1 October 2026.
Who owns Aerpace Industries Ltd?
Promoters hold 45.3% of Aerpace Industries Ltd, foreign institutions null%, domestic institutions null% and the public 54.8% (latest quarter). The biggest move on the register over the last two years: Promoters cut 5.5 points over 8 quarters. — as of 1 October 2026.
Does Aerpace Industries Ltd have too much debt?
It carries real leverage — Aerpace Industries Ltd's debt-to-equity is 1.08, and operating profit covers the interest bill −14×. FY26 borrowings were ₹40.0 Cr against equity of ₹37.0 Cr. Read the returns on this page with that leverage in mind — as of 1 October 2026.
What is Aerpace Industries Ltd's capex?
Aerpace Industries Ltd spent ₹76.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹20.0 Cr, with ₹57.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 1 October 2026.
What is Aerpace Industries Ltd's cash flow?
Aerpace Industries Ltd consumed ₹3.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−23.0 Cr). Reported profit that year was ₹−16.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 1 October 2026.
What could break the Aerpace Industries Ltd story?
Biggest watch item: the price is already 14 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 1 October 2026.
Is Aerpace Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Aerpace Industries Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 1 October 2026.
Not SEBI Registered !! Not Investment advice !!